Abstract:Background We aim to analyze the ability to detect epithelial growth factor receptor (EGFR) mutations on chest CT images of patients with lung adenocarcinoma using radiomics and/or multi-level residual convolutionary neural networks (MCNNs). Methods We retrospectively collected 1,010 consecutive patients in Shanghai Chest Hospital from 2013 to 2017, among which 510 patients were EGFR-mutated and 500 patients were wild-type. The patients were randomly divided into a training set (810 patients) and a validation set (200 patients) according to a balanced distribution of clinical features. The CT images and the corresponding EGFR status measured by Amplification Refractory Mutation System (ARMS) method of the patients in the training set were utilized to construct both a radiomics-based model (MRadiomics) and MCNNs-based model (MMCNNs). The MRadiomics and MMCNNs were combined to build the ModelRadiomics+MCNNs (MRadiomics+MCNNs). Clinical data of gender and smoking history constructed the clinical features-based model (MClinical). MClinical was then added into MRadiomics, MMCNNs, and MRadiomics+MCNNs to establish the ModelRadiomics+Clinical (MRadiomics+Clinical), the ModelMCNNs+Clinical (MMCNNs+Clinical) and the ModelRadiomics+MCNNs+Clinical (MRadiomics+MCNNs+Clinical). All the seven models were tested in the validation set to ascertain whether they were competent to detect EGFR mutations. The detection efficiency of each model was also compared in terms of area under the curve (AUC), sensitivity and specificity. Results The AUC of the MRadiomics, MMCNNs and MRadiomics+MCNNs to predict EGFR mutations was 0.740, 0.810 and 0.811 respectively. The performance of MMCNNs was better than that of MRadiomics (P=0.0225). The addition of clinical features did not improve the AUC of the MRadiomics (P=0.623), the MMCNNs (P=0.114) and the MRadiomics+MCNNs (P=0.058). The MRadiomics+MCNNs+Clinical demonstrated the highest AUC value of 0.834. The MMCNNs did not demonstrate any inferiority when compared with the MRadiomics+MCNNs (P=0.742) and the MRadiomics+MCNNs+Clinical (P=0.056). Conclusions Both of the MRadiomics and the MCNNs could predict EGFR mutations on CT images of patients with lung adenocarcinoma. The MMCNNs outperformed the MRadiomics in the detection of EGFR mutations. The combination of these two models, even added with clinical features, is not significantly more efficient than MMCNNs alone.

Identifying Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma by Three-Dimensional Convolutional Neural Networks.

CT Delta-Radiomics for Identification of Advanced EGFR-Mutated Lung Adenocarcinoma Sensitive to Therapies Targeting EGFR Pathway

Prediction of epidermal growth factor receptor (EGFR) mutation status in lung adenocarcinoma patients on computed tomography (CT) images using 3-dimensional (3D) convolutional neural network

Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer

Deep CNN Model Using CT Radiomics Feature Mapping Recognizes EGFR Gene Mutation Status of Lung Adenocarcinoma

Deep learning predicts epidermal growth factor receptor mutation subtypes in lung adenocarcinoma

Toward automatic prediction of EGFR mutation status in pulmonary adenocarcinoma with 3D deep learning

Predicting EGFR Mutation Status in Lung Adenocarcinoma on CT Image Using Deep Learning.

Implementation Strategy of a CNN Model Affects the Performance of CT Assessment of EGFR Mutation Status in Lung Cancer Patients

Deep Learning to Predict EGFR Mutation and PD-L1 Expression Status in Non-Small-Cell Lung Cancer on Computed Tomography Images

Detection of Epithelial Growth Factor Receptor (EGFR) Mutations on CT Images of Patients with Lung Adenocarcinoma Using Radiomics And/or Multi-Level Residual Convolutionary Neural Networks.

Advancing EGFR mutation subtypes prediction in NSCLC by combining 3D pretrained ConvNeXt, radiomics, and clinical features

3D Radiomics Predicts EGFR Mutation, Exon-19 Deletion and Exon-21 L858R Mutation in Lung Adenocarcinoma

Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning

Convolutional Neural Networks For Predicting Molecular Profiles Of Non-Small Cell Lung Cancer

Using Multi-phase CT Radiomics Features to Predict EGFR Mutation Status in Lung Adenocarcinoma Patients

High-resolution Computed Tomography Findings Independently Predict Epidermal Growth Factor Receptor Mutation Status in Ground-Glass Nodular Lung Adenocarcinoma.

3D Convolutional Neural Network for Differentiating Pre-Invasive Lesions from Invasive Adenocarcinomas Appearing As Ground-Glass Nodules with Diameters ≤3 Cm Using HRCT

Predicting Tyrosine Kinase Inhibitor Treatment Response in Stage IV Lung Adenocarcinoma Patients With EGFR Mutation Using Model-Based Deep Transfer Learning

Detailed identification of epidermal growth factor receptor mutations in lung adenocarcinoma: Combining radiomics with machine learning

Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling